This ASCO University® course is designed to help physicians assess the benefits and risks associated with palliative radiation. Through two practical case scenarios, experts in radiation oncology discuss treatment strategies and the decision-making process for using palliative radiation.
- Discuss the value of radiotherapy to systemic therapy in relieving pain and reducing the morbidity of bone metastases.
- Discuss the quality of life and comparative effectiveness evidence supporting the use of radiotherapy for bone metastases.
- Recommend palliative radiation in the treatment of painful bone metastases with external beam radiotherapy or stereotactic body radiotherapy.
- Identify clinical situations where palliative radiotherapy would be of value and recommend the use of this therapy to the patient
- Review the role of radiotherapy in the treatment of brain metastasis and discuss the quality-of-life implications of whole brain radiotherapy.
ACGME Competencies Addressed: Medical Knowledge, Practice-based Learning & Improvement, Interpersonal & Communication Skills, Professionalism
The American Society of Clinical Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Clinical Oncology designates this Enduring Material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A member of the ASCO CME Subcommittee has reviewed all faculty disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where they exist.
Dr. Janjan has the following to disclose: Consultant or Advisory Role: Accuray, ICON, Dendreon; Stock Ownership: Acuity Health; Honoraria: CMP Healthcare Oncology Publishing
Dr. Lutz has no relevant relationships to disclose.
Dr. Small has no relevant relationships to disclose.
Dr. Jedd Wolchok, MD (CME Reviewer) has the following to disclose: Consultant or Advisory Role: Agenus, Bristol-Myers Squibb, ZIOPHARM Oncology, Research Funding: Novartis
Date of Original Release: December 16, 2010.
Method of Instruction and Participation
This interactive, online activity allows participants to proceed through the content at a self-directed pace. Case-based scenarios with guided thought questions, faculty commentary, and presentation slides comprise the activity’s content.
Self-directed, online slide presentation with faculty audio commentary.
Estimated Time to Complete the Activity: 1.5 hours
No commercial support was obtained for this activity.